VERA - Vera Therapeutics may get January boost with phase 2 data - Cowen
- Vera Therapeutics ( NASDAQ: VERA ) is poised to surge 35%-40% following the expected January 2023 release of phase 2 data on atacicept for IgA nephropathy (IgAN), according to Cowen.
- The firm has an outperform rating on the stock.
- Analyst Ritu Baral gives a 50-50 chance that the phase 2b Origin trial of atacicept will show a statistically significant 40%-45% placebo-adjusted proteinuria reduction in the 150mg dose.
- A best case outcome of 50% reduction is given a 1-in-4 chance, the firm noted.
- However, if safety signals are reported, the stock could crash by 70% or more, Baral believes, though only gives 20% likelihood to this happening.
- Vera Therapeutics ( VERA ) has previously said the atacicept data will release in early Q1 2023.
- Seeking Alpha's Quant Rating views Vera ( VERA ) as a hold with high marks for growth and momentum .
For further details see:
Vera Therapeutics may get January boost with phase 2 data - Cowen